drugset / Trial / NCT06813079
Using Tumor Models to Determine Treatments
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to see if using Patient Derived Organoids (PDO) to choose a drug for the treatment of pancreatic cancer individually for each patient is useful. The study will look at the number of participants who have a response to their assigned drug.
Timeline
- Start
- 2025-04-07
- Primary completion
- 2028-02-17
- Completion
- 2028-02-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | Oral |
| Subject | Brigatinib | Small molecule | — | Oral |
| Subject | Ceritinib | Small molecule | — | Oral |
| Subject | Cobimetinib | Small molecule | — | Oral |
| Subject | Colchicine | Small molecule | — | — |
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |
| Subject | Etoposide | Small molecule | — | Oral |
| Subject | Neratinib | Small molecule | — | Oral |
| Subject | Ponatinib | Small molecule | — | Oral |
| Subject | Selinexor | Other / unclassified | — | Oral |